Spero Therapeutics (NASDAQ:SPRO – Get Rating) announced its quarterly earnings data on Monday. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.14), MarketWatch Earnings reports. Spero Therapeutics had a negative net margin of 491.65% and a negative return on equity of 87.72%. During the same period in the […]

Related Keywords

United States , , Geode Capital Management , Goldman Sachs Group Inc , Zacks Investment Research , Vanguard Group Inc , Aquilo Capital Management Llc , Spero Therapeutics Inc , Dimensional Fund Advisors , Spero Therapeutics , Get Rating , Marketwatch Earnings , Investment Research , Aquilo Capital Management , Street Corp , Capital Management , Fund Advisors , Goldman Sachs Group , Sachs Group , Nasdaq Spro , Aspro , Medical , Earnings ,